A novel model of venous thrombosis in the vena cava of rabbits

Journal of Pharmacological and Toxicological Methods

Volumn 39, Issue 4, 1998, Pages 193-202

  Chi, Liguo ^a   Saganek, Lori J ^a   Rogers, Karen L ^a   Mertz, Thomas E ^a   Metz, Alan L ^a   Uprichard, Andrew C G ^a   Gallagher, Kim P ^a  

^a PFIZER INC   (United States)

Author keywords

Animal model; Low molecular weight heparin; Rabbit; Shunt; Thrombosis; Vena cava; Venous blood flow

Indexed keywords

ENOXAPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL SHUNT; CAVA VEIN; EXPERIMENTAL MODEL; MALE; NONHUMAN; RABBIT; REPRODUCIBILITY; THROMBUS; VEIN THROMBOSIS;

ANIMALS; BLEEDING TIME; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; ENOXAPARIN; FIBRINOLYTIC AGENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; LAPAROTOMY; MALE; MICROSCOPY, ELECTRON; RABBITS; VENA CAVA, SUPERIOR; VENOUS THROMBOSIS;

EID: 0031756199     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(98)00024-0     Document Type: Article

References (20)

1. Anderson H.V., Willerson J.T. Experimental models of thrombosis. Loscalzo J., Schafer A.I. Thrombosis and Hemorrhage. 1994;385-393 Blackwell Scientific Publications Inc, Boston.
2. Aronson D.L., Thomas D.P. Experimental studies on venous thrombosis effect of coagulants, procoagulants and vessel contusion . Thromb Haemost. 54:1985;866-870.
3. Bergqvist D., Benoni G., Bjorgell O., Fredin H., Hedlundh U., Nicolas S., Nilsson P., Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 335:1996;696-700.
4. Carter C.J. The pathophysiology of venous thrombosis. Prog Cardiovasc Dis. 36:1994;439-446.
5. Chi L, Rebello S, Lucchesi BR (1998) In vivo models of thrombosis. In Handbook of Experimental Pharmacology. Eds., ACG Uprichard and KP Gallagher. Heidelberg: Springer-Verlag, GmbH & Co., pp. (in press).
6. Chi L., Rogers K.L., Uprichard A.C.G., Gallagher K.P. The therapeutic potential of novel anticoagulants. Exp Opin Invest Drugs. 6:1997;1591-1622.
7. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. DX-9065, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost. 74:1995;635-639.
8. Harker L.A., Hanson S.R., Kelly A.B. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost. 78:1997;736-741.
9. Hirsh J., Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Circulation. 93:1996;2212-2245.
10. Hollenbach S., Sinha U., Lin P.H., Needham K., Frey J., Hancock T., Wong A., Wolf D. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Haemost. 71:1994;357-362.
11. Knabb R.M., Kettner C.A., Timmermans P.B.M.W.M., Reilly T.M. In vivo characterization of a new synthetic thrombin inhibitor. Thromb Haemost. 67:1992;56-59.
12. Moriau M., Lavenne-Pardonge E., Crasborn L., von Frenckell R., Col-Debeys C. The treatment of severe or recurrent deep venous thrombosis. Thromb Res. 78:1995;469-482.
13. Noble S., Peters D.H., Goa K.L. Enoxaparin. Drugs. 49:1995;388-410.
14. Scott N.A., Nunes G.L., King S.B.I., Harker L.A. Local delivery of an antithrombin prevents platelet-dependent thrombosis. Circulation. 90:1994;1951-1955.
15. Spokas E.G., Wun T.C. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. J Pharmacol Toxicol Methods. 27:1992;225-232.
16. 2] prevents arterial but not venous rethrombosis. J Cardiovasc Pharmacol. 26:1995;241-250.
17. Thomas D.P. Pathogenesis of venous thrombosis. Bloom A.L., Forbes C.D., Thomas D.P., Tuddenham E.G.D. Haemostasis and Thrombosis. 1994;1335-1347 Churchill Livingstone, Edinburgh.
18. Thomas D.P. Venous thrombosis and the "Wessler test." Thromb Haemost. 76:1996;1-4.
19. Vaughan D.E., Collen D., Gold H.K. Experimental models of thrombolysis. Loscalzo J., Schafer A.I. Thrombosis and Hemorrhage. 1994;395-404 Blackwell Scientific Publications Inc, Boston.
20. Yokoyama T., Kelly A.B., Marzec U.M., Hanson S.R., Kunitada S., Harker L.A. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation. 92:1995;485-491.